Pfizer ends Trillium-related development as R&D spend jumps
研发支出激增之际，辉瑞叫停与延龄草治疗有限公司相关的研发项目

Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies.
辉瑞已停止源自其2021年收购延龄草治疗有限公司的最后一项临床研究，并将资金主要转投至一系列其他肿瘤和肥胖研究。